Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Euvichol-S Extended Dosing Intervals in Kenya
NCT07487077Phase 4Recruiting
- Sponsor
- Sabin Vaccine Institute
- Start
- Oct 2025
- Primary completion
- Jun 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Killed bivalent (O1 and O139) whole cell oral cholera vaccine in cholera, sponsored by Sabin Vaccine Institute. Started Oct 2025; status: recruiting.
02
Drugs
Killed bivalent (O1 and O139) whole cell oral cholera vaccine
03
Conditions
cholera
Beyond the preview
Go deeper on NCT07487077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07487077.